AbCellera and Biogen link on neurological antibody therapy

12 Mar 2024
www.pharmaceutical-technology.com
Orphan DrugLicense out/in
AbCellera and Biogen link on neurological antibody therapy
Preview
Source: Pharmaceutical Technology
AbCellera and Biogen will execute the discovery and development of antibodies for neurological conditions. Credit: Gorodenkoff / Shutterstock.com.
AbCellera has entered a partnership with Biogen to discover therapeutic antibodies for neurological ailments.
The companies will execute the discovery and development of antibodies for a new target that will aid in offering brain biotherapeutics for neurological indications.
AbCellera will receive an upfront payment from Biogen.
Biogen will also make milestone payments when research programmes meet specific research, developmental and regulatory goals, apart from royalty payments on future net product sales.
AbCellera leverages a new approach to discover antibody drugs to expedite the development of treatment options.
See Also:
Pearl Bio and Merck partner for discovery of cancer therapies
AbCellera and Biogen link on neurological antibody therapy
Preview
Source: Pharmaceutical Technology
Terns scores FDA orphan designation for CML therapy
AbCellera and Biogen link on neurological antibody therapy
Preview
Source: Pharmaceutical Technology
The company’s integrated engine combines expertise, technology and data science to advance antibody-based treatments across a range of therapeutic areas.
The collaboration with Biogen leverages AbCellera’s expertise in complex challenges in neurological disease.
In November 2023, AbCellera signed a multi-year, multi-programme deal with Prelude Therapeutics.
The collaboration focuses on the discovery, development and marketing of treatments for cancer patients.
Prelude contributes its expertise in targeted protein degradation and AbCellera provides its antibody discovery engine to develop novel precision antibody-drug conjugates.
AbCellera Partnering senior vice-president Murray McCutcheon stated: “Delivering biologics across the blood-brain barrier is one of the most important and long-standing problems in neuroscience.
“We are excited to work with Biogen on this innovative programme, which has the potential to unlock multiple new approaches to treating neurological conditions.”
In September 2023, AbCellera also initiated a strategic collaboration with Incyte, targeting the discovery and development of therapeutic antibodies in oncology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.